BRAIN Biotech AG Financial Results H1 2021 / 22 | Highlights, ESG and Mid-Term Targets with IR episode artwork

EPISODE · Jun 4, 2022 · 18 MIN

BRAIN Biotech AG Financial Results H1 2021 / 22 | Highlights, ESG and Mid-Term Targets with IR

from Investor Insights from CEOs & CFOs | seat11a · host seat11a.com

BRAIN Biotech AG H1 2021/22: Key Takeaways Overview of Brain Biotech AG’s H1-22 Highlights and More IR Michael Schneiders provides an overview of Brain Biotech AG’s H1-22 Highlights, PHA121, Incubator Exits, and more in this financial results presentation. He highlights the Q2-Highlights and the company’s commitment to ESG+. Michael also shares five key points related to ESG+ and the company’s targets for 2032/2050.   Michael shares five key points related to ESG+ and the company’s targets for 2032/2050, demonstrating the company’s commitment to sustainable and responsible business practices.   Discussion on the ESG Opportunity, exploring the potential and significance of ESG in the current market and future prospects.   Michael discusses the Brain Incubator, which includes exciting projects like the Urban Mining Project and Genome Editing, showcasing the innovative approaches and initiatives taken by Brain Biotech AG.   Michael analyses the H1 2021/22 Financial Highlights, including cash and cash flow, long-term revenue growth trajectory, and the impact of Covid, Supply Chain, and Inflation, providing insights into the financial stability and challenges faced by Brain Biotech AG.   Finally, Michael concludes the presentation by providing FY21/22 Guidance and Mid-Term Targets for Brain Biotech AG. Overall, this presentation is an excellent resource for anyone interested in learning more about Brain Biotech AG and its financial performance, ESG commitments, and prospects. ESG+ Commitments and TargetsKey Points Related to ESG+ and Targets for 2032/2050Exploring ESG Opportunities and Brain Incubator ProjectsThe ESG OpportunityBrain Incubator and Its ProjectsAnalysis of H1 2021/22 Financial HighlightsConcluding with FY21/22 Guidance and Mid-Term Targets ================================= ▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ ================================= T&C This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Episode metadata supplied by the publisher feed · Published Jun 4, 2022

Embed this episode

Ready to play

BRAIN Biotech AG Financial Results H1 2021 / 22 | Highlights, ESG and Mid-Term Targets with IR

0:00 18:48

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Investor Insights from CEOs & CFOs | seat11a?

This episode is 18 minutes long.

When was this Investor Insights from CEOs & CFOs | seat11a episode published?

This episode was published on June 4, 2022.

Can I download this Investor Insights from CEOs & CFOs | seat11a episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!